Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

2021 ◽  
Author(s):  
Yosuke Kawashima ◽  
Tatsuro Fukuhara ◽  
Haruhiro Saito ◽  
Naoki Furuya ◽  
Kana Watanabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 3 ◽  
Multicentre Phase ◽  
Egfr Mutant ◽  
Overall Survival Analysis

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

2018 ◽  
Vol 54 (1) ◽  
pp. 10-17
Author(s):  
Filipa Aguiar ◽  
Gabriela Fernandes ◽  
Henrique Queiroga ◽  
José Carlos Machado ◽  
Luís Cirnes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated ◽  
Overall Survival Analysis

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

2015 ◽  
Vol 16 (3) ◽  
pp. 328-337 ◽  
Author(s):  
Luis Paz-Ares ◽  
Jörg Mezger ◽  
Tudor E Ciuleanu ◽  
Jürgen R Fischer ◽  
Joachim von Pawel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document